Related references
Note: Only part of the references are listed.Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept
Mitra Abbasi et al.
TOXICOLOGY MECHANISMS AND METHODS (2017)
Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept
Mitra Abbasi et al.
TOXICOLOGY MECHANISMS AND METHODS (2017)
Significance of integrated in silico transmural ventricular wedge preparation models of human non-failing and failing hearts for safety evaluation of drug candidates
Taeko Kubo et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2017)
A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes
Hiroyuki Ando et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2017)
Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity
Barbara Wisniowska et al.
DRUG DISCOVERY TODAY (2017)
Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms
M. Cummins Lancaster et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes
Stefan A. Mann et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2016)
An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel
William J. Crumb et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2016)
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative Update on progress
Thomas Colatsky et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2016)
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm
Bernard Fermini et al.
JOURNAL OF BIOMOLECULAR SCREENING (2016)
A Human Ventricular Myocyte Model with a Refined Representation of Excitation-Contraction Coupling
Yukiko Himeno et al.
BIOPHYSICAL JOURNAL (2015)
A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment
Hitesh B. Mistry et al.
FRONTIERS IN PHARMACOLOGY (2015)
Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator
Jun-ichi Okada et al.
SCIENCE ADVANCES (2015)
In silico Study of Transmural Dispersion of Repolarization in Non-failing Human Ventricular Myocytes: Contribution to Cardiac Safety Pharmacology
Bernard Christophe
BRITISH JOURNAL OF PHARMACEUTICAL RESEARCH (2015)
Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium
Philip T. Sager et al.
AMERICAN HEART JOURNAL (2014)
Screening for Acute IKr Block Is Insufficient to Detect Torsades de Pointes Liability Role of Late Sodium Current
Tao Yang et al.
CIRCULATION (2014)
Prediction of Thorough QT study results using action potential simulations based on ion channel screens
Gary R. Mirams et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2014)
In silico assessment of drug safety in human heart applied to late sodium current blockers
Beatriz Trenor et al.
CHANNELS (2013)
Simulation of early after-depolarisation in non-failing human ventricular myocytes: Can this help cardiac safety pharmacology?
Bernard Christophe
PHARMACOLOGICAL REPORTS (2013)
MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes
James Kramer et al.
SCIENTIFIC REPORTS (2013)
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk
Gary R. Mirams et al.
CARDIOVASCULAR RESEARCH (2011)
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation
Gary Gintant
PHARMACOLOGY & THERAPEUTICS (2011)
Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation
Thomas O'Hara et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
A novel computational model of the human ventricular action potential and Ca transient
Eleonora Grandi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Blockade of the IKs potassium channel: An overlooked cardiovascular liability in drug safety screening?
Rob Towart et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2009)
Alfuzosin delays cardiac repolarization by a novel mechanism
Antonio E. Lacerda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes
Charles Antzelevitch
EUROPACE (2007)
Cell model for efficient simulation of wave propagation in human ventricular tissue under normal and pathological conditions
K. H. W. J. Ten Tusscher et al.
PHYSICS IN MEDICINE AND BIOLOGY (2006)
The mechanism of pause-induced torsade de pointes in long QT syndrome
JQ Liu et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2005)
Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres
P Champeroux et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties
C Antzelevitch et al.
CIRCULATION (2004)
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
WS Redfern et al.
CARDIOVASCULAR RESEARCH (2003)
Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent?
S Viskin et al.
HEART (2000)
Share Paper
